Translational Science and Therapeutics Division

Accelerating Clinical Advances in Cellular and Gene Therapies

The Translational Science and Therapeutics (TST) Division at Fred Hutchinson Cancer Center is composed primarily of laboratory-based research groups that work in areas related to hematopoiesis, immunology, hematopoietic cell transplantation, immunotherapy and gene therapy. The overall goal is to advance our understanding in these research areas and to develop next generation therapies for patients with hematologic malignancies and disorders, solid tumors and infectious diseases.

Dr. Geoff hill writes on a whiteboard

Advancing Research

Our faculty includes 49 researchers focused on developing treatment options, improving patient outcomes and identifying ways to prevent complications from treatments.

Dr. Stan Riddell looks through a microscoope

Developing Therapies

Our investigators are addressing less toxic techniques for eliminating diseased cancer cells and improving the chance of matching blood products for transplantation.

Latest TST News

All TST News
50 years of doing hard things Founded in 1975 to honor a brother, Fred Hutch Cancer Center pursued bold science, pioneered a cure for blood diseases that changed medicine and became a world-class biomedical research and clinical care institution January 9, 2025
Leonard and Norma Klorfine Endowed Chair for Clinical Research awarded to Dr. Geoffrey Hill Funding will help facilitate inter-institutional collaboration and foundational data capture for immunological research January 7, 2025
Cracking the sparkle code Fred Hutch cancer biologist wins V Foundation Scholar Award to explore role of protein sugaring in leukemia tumors that survive chemotherapy December 11, 2024
New initiative bolsters Washington state life sciences Fred Hutch researchers awarded over $4M in grants from the Washington Research Foundation November 13, 2024